IGHE and Alzheimer disease: Although the role of allergens in AD is still controversial and at the moment the stratification of response to anti-IL-31RA depending on IgE status has not been performed, it can be hypothesized that assessing specific IgE status to HDM in candidates for anti-IL-31RA therapy may eventually be helpful for identifying patients more prone to good clinical response to anti-IL-31RA and with a more favorable response in comparison to dupilumab or JAK inhibitors.